港股異動 | 錦欣生殖(1951.HK)漲7.64% 完成配售為加速併購提供支持
格隆匯2月19日丨入選了格隆匯2021年“下注中國”十大核心潛力資產名單的錦欣生殖(1951.HK)漲7.64%,報21.85港元,總市值548億港元。華創證券發佈研究報吿,首予錦欣生殖目標價21.6港元,評級“推薦”。報吿中稱,錦欣生殖近日公佈,與配售代理訂立配售協議,以每股15.85港元配售8000萬股,約佔公司已發行股本的3.29%,所得款項預計為12.68億港元,用途為併購我國東部、京津冀、其他高潛力等地區,東南亞等亞太國家的ARS機構。該行表示,輔助生殖行業發展主要驅動力為IVF滲透率提升、不孕不育發病率提升,兩者均帶來較大提升空間。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.